nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadobenate Dimeglumine—Sweating—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Gadobenate Dimeglumine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Gadobenate Dimeglumine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Fludarabine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gadobenate Dimeglumine—Inflammation—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gadobenate Dimeglumine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gadobenate Dimeglumine—Pain—Fludarabine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Fludarabine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Gadobenate Dimeglumine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gadobenate Dimeglumine—Respiratory failure—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gadobenate Dimeglumine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gadobenate Dimeglumine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Gadobenate Dimeglumine—Flushing—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Teniposide—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Teniposide—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gadobenate Dimeglumine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadobenate Dimeglumine—Cough—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Teniposide—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gadobenate Dimeglumine—Chills—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gadobenate Dimeglumine—Ecchymosis—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gadobenate Dimeglumine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Gadobenate Dimeglumine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadobenate Dimeglumine—Tremor—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gadobenate Dimeglumine—Infection—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Teniposide—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Fludarabine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gadobenate Dimeglumine—Rash—Teniposide—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Teniposide—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Gadobenate Dimeglumine—Headache—Teniposide—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Vincristine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Teniposide—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Vincristine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Gadobenate Dimeglumine—Cough—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Gadobenate Dimeglumine—Infection—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Fludarabine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Gadobenate Dimeglumine—Rash—Fludarabine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Fludarabine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gadobenate Dimeglumine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gadobenate Dimeglumine—Pain—Bleomycin—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gadobenate Dimeglumine—Headache—Fludarabine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Anxiety—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Gadobenate Dimeglumine—Infection—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Fludarabine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadobenate Dimeglumine—Infection—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Gadobenate Dimeglumine—Shock—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Gadobenate Dimeglumine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Vincristine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Gadobenate Dimeglumine—Pain—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Bleomycin—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadobenate Dimeglumine—Pain—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadobenate Dimeglumine—Asthma—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Bleomycin—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gadobenate Dimeglumine—Pain—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Gadobenate Dimeglumine—Constipation—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Carmustine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Gadobenate Dimeglumine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Vincristine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000992	0.000992	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00099	0.00099	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000987	0.000987	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000987	0.000987	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Bleomycin—lymphatic system cancer	0.000978	0.000978	CcSEcCtD
Gadobenate Dimeglumine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Gadobenate Dimeglumine—Infestation—Methotrexate—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Gadobenate Dimeglumine—Rash—Bleomycin—lymphatic system cancer	0.00097	0.00097	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Bleomycin—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Carmustine—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Gadobenate Dimeglumine—Renal failure—Methotrexate—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Gadobenate Dimeglumine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000948	0.000948	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Gadobenate Dimeglumine—Sweating—Methotrexate—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Gadobenate Dimeglumine—Haematuria—Methotrexate—lymphatic system cancer	0.00093	0.00093	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Vincristine—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Carmustine—lymphatic system cancer	0.000919	0.000919	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Bleomycin—lymphatic system cancer	0.000914	0.000914	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000896	0.000896	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Carmustine—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Vincristine—lymphatic system cancer	0.000877	0.000877	CcSEcCtD
Gadobenate Dimeglumine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Gadobenate Dimeglumine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000854	0.000854	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Carmustine—lymphatic system cancer	0.000854	0.000854	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Vincristine—lymphatic system cancer	0.000848	0.000848	CcSEcCtD
Gadobenate Dimeglumine—Rash—Carmustine—lymphatic system cancer	0.000847	0.000847	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Carmustine—lymphatic system cancer	0.000846	0.000846	CcSEcCtD
Gadobenate Dimeglumine—Visual impairment—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Gadobenate Dimeglumine—Headache—Carmustine—lymphatic system cancer	0.000841	0.000841	CcSEcCtD
Gadobenate Dimeglumine—Eye disorder—Methotrexate—lymphatic system cancer	0.000818	0.000818	CcSEcCtD
Gadobenate Dimeglumine—Tinnitus—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Vincristine—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Gadobenate Dimeglumine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Gadobenate Dimeglumine—Rash—Vincristine—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Vincristine—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Gadobenate Dimeglumine—Headache—Vincristine—lymphatic system cancer	0.000803	0.000803	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Carmustine—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Gadobenate Dimeglumine—Angiopathy—Methotrexate—lymphatic system cancer	0.000794	0.000794	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000794	0.000794	CcSEcCtD
Gadobenate Dimeglumine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Gadobenate Dimeglumine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000789	0.000789	CcSEcCtD
Gadobenate Dimeglumine—Rash—Mitoxantrone—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Gadobenate Dimeglumine—Chills—Methotrexate—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Gadobenate Dimeglumine—Headache—Mitoxantrone—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Gadobenate Dimeglumine—Mental disorder—Methotrexate—lymphatic system cancer	0.000767	0.000767	CcSEcCtD
Gadobenate Dimeglumine—Malnutrition—Methotrexate—lymphatic system cancer	0.000762	0.000762	CcSEcCtD
Gadobenate Dimeglumine—Erythema—Methotrexate—lymphatic system cancer	0.000762	0.000762	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Vincristine—lymphatic system cancer	0.000762	0.000762	CcSEcCtD
Gadobenate Dimeglumine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Mitoxantrone—lymphatic system cancer	0.000742	0.000742	CcSEcCtD
Gadobenate Dimeglumine—Back pain—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Gadobenate Dimeglumine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000707	0.000707	CcSEcCtD
Gadobenate Dimeglumine—Anaemia—Methotrexate—lymphatic system cancer	0.000705	0.000705	CcSEcCtD
Gadobenate Dimeglumine—Malaise—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Gadobenate Dimeglumine—Leukopenia—Methotrexate—lymphatic system cancer	0.000682	0.000682	CcSEcCtD
Gadobenate Dimeglumine—Cough—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Gadobenate Dimeglumine—Chest pain—Methotrexate—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Gadobenate Dimeglumine—Myalgia—Methotrexate—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Gadobenate Dimeglumine—Arthralgia—Methotrexate—lymphatic system cancer	0.000649	0.000649	CcSEcCtD
Gadobenate Dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000644	0.000644	CcSEcCtD
Gadobenate Dimeglumine—Discomfort—Methotrexate—lymphatic system cancer	0.000641	0.000641	CcSEcCtD
Gadobenate Dimeglumine—Confusional state—Methotrexate—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Gadobenate Dimeglumine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000622	0.000622	CcSEcCtD
Gadobenate Dimeglumine—Infection—Methotrexate—lymphatic system cancer	0.000618	0.000618	CcSEcCtD
Gadobenate Dimeglumine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00061	0.00061	CcSEcCtD
Gadobenate Dimeglumine—Skin disorder—Methotrexate—lymphatic system cancer	0.000604	0.000604	CcSEcCtD
Gadobenate Dimeglumine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000601	0.000601	CcSEcCtD
Gadobenate Dimeglumine—Hypotension—Methotrexate—lymphatic system cancer	0.000581	0.000581	CcSEcCtD
Gadobenate Dimeglumine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Gadobenate Dimeglumine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000559	0.000559	CcSEcCtD
Gadobenate Dimeglumine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000555	0.000555	CcSEcCtD
Gadobenate Dimeglumine—Somnolence—Methotrexate—lymphatic system cancer	0.000553	0.000553	CcSEcCtD
Gadobenate Dimeglumine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Gadobenate Dimeglumine—Fatigue—Methotrexate—lymphatic system cancer	0.000536	0.000536	CcSEcCtD
Gadobenate Dimeglumine—Pain—Methotrexate—lymphatic system cancer	0.000532	0.000532	CcSEcCtD
Gadobenate Dimeglumine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000513	0.000513	CcSEcCtD
Gadobenate Dimeglumine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000509	0.000509	CcSEcCtD
Gadobenate Dimeglumine—Urticaria—Methotrexate—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Gadobenate Dimeglumine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Gadobenate Dimeglumine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Gadobenate Dimeglumine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000458	0.000458	CcSEcCtD
Gadobenate Dimeglumine—Asthenia—Methotrexate—lymphatic system cancer	0.000446	0.000446	CcSEcCtD
Gadobenate Dimeglumine—Pruritus—Methotrexate—lymphatic system cancer	0.00044	0.00044	CcSEcCtD
Gadobenate Dimeglumine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000426	0.000426	CcSEcCtD
Gadobenate Dimeglumine—Dizziness—Methotrexate—lymphatic system cancer	0.000411	0.000411	CcSEcCtD
Gadobenate Dimeglumine—Vomiting—Methotrexate—lymphatic system cancer	0.000396	0.000396	CcSEcCtD
Gadobenate Dimeglumine—Rash—Methotrexate—lymphatic system cancer	0.000392	0.000392	CcSEcCtD
Gadobenate Dimeglumine—Dermatitis—Methotrexate—lymphatic system cancer	0.000392	0.000392	CcSEcCtD
Gadobenate Dimeglumine—Headache—Methotrexate—lymphatic system cancer	0.00039	0.00039	CcSEcCtD
Gadobenate Dimeglumine—Nausea—Methotrexate—lymphatic system cancer	0.00037	0.00037	CcSEcCtD
